arrow_back Back Filing freshness 10-Q Q3 FY2026 SEC EDGAR

Krystal Biotech, Inc.

KRYS
$300.17 ▼ -10.60 (-3.41%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
38 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
85
Health
Excellent
Bullish
auto_awesome

Analytical Summary

Krystal Biotech, Inc. shows strong fundamentals with top-quartile Return on Common Equity (%) and Profit Margin (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $8.9B
Dividend Yield —
Revenue Growth 30.2% ↗
Op. Margin 55.9% ↗
ROIC 3.9% ↗
FCF / Share $3.05 ↗
Trailing P/E 140.9x
Price / Book 6.2x
FCF Yield 1.0%
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

38-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$127.34M
↑ +30.2% —
Net Income Profit after all expenses
$55.93M
↑ +56.5% —
Operating Margin Operating profit as % of sales
55.9%
↑ +14.0% 94th
FCF / Share Free cash flow per share
$3.05
↑ +26.4% —
Long-Term Debt Long-term obligations
$4.25M
— 0.0% —
trending_up

Bullish Indicators

  • Operating Margin (%)Operating Margin (%) is in the top quartile
  • Profit Margin (%)Profit Margin (%) is in the top quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability ↑
97
Returns
83
Cash Quality ↓
62

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 9 years · 38 quarters